Developer docs
API playgroundTry for free, no card

Search company profiles

Carbogen Amcis

Full company profile

uuid000ab9q

Namestring
Carbogen Amcis
Legal namestring
CARBOGEN AMCIS AG
Company typeenum
Private
Founded yearint
1987
Descriptiontext

Carbogen Amcis is a Swiss pharmaceutical contract development and manufacturing organization (CDMO) headquartered in Bubendorf, Switzerland, founded in 1987 and operating as a wholly-owned subsidiary of Dishman Carbogen Amcis Limited (India) since 2006. The company provides integrated drug substance and drug product services to pharmaceutical and biopharmaceutical customers, spanning non-GMP development, clinical and commercial API manufacturing, sterile injectable drug product manufacturing, and specialty chemicals (vitamin D analogs and cholesterol/lanolin derivatives). It operates eight manufacturing sites across Switzerland, the United Kingdom, France, the Netherlands, and China, with more than 2,000 employees globally.

The company's technology platform centers on specialized capabilities including highly potent API manufacturing down to 0.05µg/m3 OEL using barrier isolation technology, antibody drug conjugate (ADC) bioconjugation services, Simulated Moving Bed chromatography refined over 20 years, flow chemistry, crystallization process development, and Annex 1-compliant sterile drug product manufacturing including lyophilization. Reactor capacity ranges from 1L laboratory scale to 6,300L commercial production. The company maintains consistent clean inspection records across FDA, Swissmedic, NMPA, ANSM, ANVISA, and ISO 22716 audits across all major sites.

Carbogen Amcis operates a B2B, project-based professional services model with typical payment milestones structured as 40% on order acceptance, 50% on service completion, and 10% on report delivery. Revenue is generated through direct enterprise engagement with pharmaceutical and biopharmaceutical customers across horizontal segments (drug substance, drug product, specialty chemicals), supported by co-investment agreements with select anchor clients. The company goes to market through direct sales and account management, industry conference presence (CPhI, BIO-Europe, ChemOutsourcing, ISPE), and content marketing via its knowledge center, with no third-party distribution channels.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
501–1,000
akta.pro rankint
HeadquartersBubendorf, Switzerland
HQ citystring
Bubendorf
HQ countrystring
Switzerland
HQ regionstring
Europe
Markets served

Serves global market

Offices9 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
contract pharmaceutical manufacturing, API development services, sterile drug product manufacturing, highly potent API manufacturing, antibody drug conjugate services
Industry4 codes
PRIMARYHLAGABAA
Small-Molecule API & Intermediates CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
SECONDARYHLAGABAB
Small-Molecule Drug Product (Solid/Oral/Parenteral) CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
SECONDARYHLAGABAG
Drug Substance–Drug Product Integrated CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
SECONDARYHLAGABAC
Biologics (mAbs/Recombinant Proteins) CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
NAICS code3 codes
  • Pharmaceutical Preparation Manufacturing325412
  • Biological Product (except Diagnostic) Manufacturing325414
  • Pharmaceutical and Medicine Manufacturing32541
SIC code1 code
  • Pharmaceutical Preparations2834
Product category
Pharmaceutical Contract Development and Manufacturing (CDMO)
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model2 records
1Contract Development and Manufacturing Services
TypeProfessional Services
Description

CDMO services for drug substance and drug product development and manufacturing, including clinical and commercial API production, sterile drug product manufacturing, and analytical services. Revenue generated through project-based contracts, typically with upfront payments (40%), milestone payments (50%), and final payments (10%) upon delivery of reports.

carbogen-amcis.com
2Specialty Chemicals (Vitamin D and Cholesterol)
TypeOne Time License
Description

Production and sale of Vitamin D analogs, Vitamin D2, cholesterol, and lanolin derivatives for pharmaceutical, cosmetic, food supplement, and industrial applications.

carbogen-amcis.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Personnel, Operations, Infrastructure, Supply Chain, Technology or R&D, Marketing or Sales
Pricing details2 tiers
1Clinical Trial Phase Services - Custom project pricing
ModelOtherBilling cadenceMulti-year contract
Notes

Payment schedule: 40% initial payment upon acceptance and prior to commencement; 50% upon completion of services; 10% upon delivery of written Report. Service Fee excludes taxes, duties, VAT, customs, insurance, disposal costs, third-party specialist work, raw materials, and primary packaging materials.

carbogen-amcis.com
2ISPE Workshop Participation
ModelOtherBilling cadenceMulti-year contract
Notes

ISPE DACH Workshop 2026: 500 EUR for ISPE members, 800 EUR for non-members (includes one-year ISPE membership)

carbogen-amcis.com
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

Carbogen Amcis is a pharmaceutical Contract Development and Manufacturing Organization (CDMO) providing integrated drug substance (API) and drug product development and manufacturing services. It serves pharmaceutical and biopharmaceutical companies with capabilities spanning non-GMP and GMP API manufacturing, sterile injectable drug product manufacturing, highly potent compound handling, ADC/bioconjugation, and specialty Vitamin D and cholesterol products, across 8 manufacturing sites in Europe and China.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • Successful completion of unannounced NMPA GMP inspection with no observations identified at Shanghai facility
+3 more records
Product overview1 text field

CARBOGEN AMCIS is a Contract Development and Manufacturing Organization (CDMO) offering integrated pharmaceutical services from drug substance to drug product. The portfolio consists of three core service pillars: Drug Substance CDMO (API development and manufacturing), Sterile Drug Product CDMO (injectable drug manufacturing), and Cholesterol & Vitamin D Specialities. Supporting these core areas are specialized capability modules including SPRINT early-phase services, Highly Potent API manufacturing, ADC & Bioconjugation, Chromatography, Flow Chemistry, and Crystallization. The company operates 8 manufacturing sites across Switzerland, UK, France, Netherlands, and China, providing services from gram-scale development through commercial production up to multi-tonne scale.

Product and service7 records
1Drug Substance CDMO Services
CategoryDrug Substance / API Development and Manufacturing
2Sterile Drug Product CDMO Services
CategorySterile Drug Product Manufacturing
3SPRINT Early-Phase Development Services
CategoryEarly-Phase API Development Services
4Highly Potent API (HiPo) Manufacturing
CategoryHigh-Potency API Manufacturing
5ADC & Bioconjugation Services
CategoryBiological Conjugate Manufacturing
6Vitamin D Analogs and Vitamin D2
CategorySpecialty Chemicals / Vitamin D APIs
7Cholesterol and Lanolin Derivatives
CategorySpecialty Chemicals / Cholesterol and Lanolin
Scale indicator9 records

Each record includes

Type, Value, Description, Source

Partnership1 partner
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-10-27
Description

Strategic alliance between Celonic Group and CARBOGEN AMCIS AG to develop and manufacture antibody drug conjugates (ADCs). The partnership aims to create an integrated ADC development platform amid rising demand, leveraging their respective expertise and expanding infrastructure to improve speed and quality.

Recent move11 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Global contract services group with CDMO capabilities spanning API development, HPAPI, and drug product services. Comparable as a broader-incumbent CDMO with overlapping capabilities but operating as part of a much larger diversified testing/services platform.

TypeDirect peer
Description

UK-headquartered CDMO specializing in small-molecule API development and HPAPI manufacturing. Closely comparable on UK-based HPAPI operations and overlap with Carbogen's Manchester site.

3Recipharm
TypeDirect peer
Description

European CDMO offering integrated drug substance and drug product services including sterile fill-finish. Comparable as a multi-site European CDMO targeting pharma customers with similar project-based service model.

TypeDirect peer
Description

China-based large-scale CDMO subsidiary of WuXi AppTec offering end-to-end small-molecule API and drug product services. Comparable as a CDMO peer of similar integrated scope with significant Asian manufacturing capacity overlapping Carbogen's Shanghai presence.

TypeDirect peer
Description

Indian-headquartered CDMO with strong HPAPI and ADC capabilities across global sites. Comparable on HPAPI specialization, ADC services, and Indian ownership/operational heritage similar to Dishman Carbogen Amcis.

TypeDirect peer
Description

German CDMO providing solid dosage forms, sterile fill-finish, and API services for pharma customers. Comparable as a mid-sized European integrated CDMO serving similar big-pharma customer base.

TypeDirect peer
Description

Privately-held Portuguese CDMO specializing in API development, HPAPI handling, and particle engineering. Closely comparable on specialty HPAPI capabilities, integrated drug substance-drug product services, and family-owned private ownership profile.

TypeBroad incumbent
Description

Swiss-headquartered global CDMO leader with massive small-molecule API, biologics, and cell-and-gene therapy manufacturing footprint. Comparable as a larger Swiss CDMO operating across overlapping modalities, but orders of magnitude larger and serving biotech as well as big pharma.

TypeDirect peer
Description

Swiss-headquartered integrated small-molecule CDMO with drug substance and drug product services across multiple global sites. Most directly comparable peer given shared Swiss heritage, integrated DS+DP model, and similar enterprise-scale customer mix.

TypeDirect peer
Description

US-based small-molecule API CDMO acquired by Permira. Directly comparable on small-molecule API development, HPAPI capabilities, and analytical services for pharma clients across clinical and commercial stages.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks1 record

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers5 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature7 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles9 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries4 records

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

Compliance7 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Carbogen Amcis

Pharmaceutical Contract Development and Manufacturing (CDMO)carbogen-amcis.com

What Carbogen Amcis does

Carbogen Amcis is a Swiss pharmaceutical contract development and manufacturing organization (CDMO) headquartered in Bubendorf, Switzerland, founded in 1987 and operating as a wholly-owned subsidiary of Dishman Carbogen Amcis Limited (India) since 2006. The company provides integrated drug substance and drug product services to pharmaceutical and biopharmaceutical customers, spanning non-GMP development, clinical and commercial API manufacturing, sterile injectable drug product manufacturing, and specialty chemicals (vitamin D analogs and cholesterol/lanolin derivatives). It operates eight manufacturing sites across Switzerland, the United Kingdom, France, the Netherlands, and China, with more than 2,000 employees globally.

The company's technology platform centers on specialized capabilities including highly potent API manufacturing down to 0.05µg/m3 OEL using barrier isolation technology, antibody drug conjugate (ADC) bioconjugation services, Simulated Moving Bed chromatography refined over 20 years, flow chemistry, crystallization process development, and Annex 1-compliant sterile drug product manufacturing including lyophilization. Reactor capacity ranges from 1L laboratory scale to 6,300L commercial production. The company maintains consistent clean inspection records across FDA, Swissmedic, NMPA, ANSM, ANVISA, and ISO 22716 audits across all major sites.

Carbogen Amcis operates a B2B, project-based professional services model with typical payment milestones structured as 40% on order acceptance, 50% on service completion, and 10% on report delivery. Revenue is generated through direct enterprise engagement with pharmaceutical and biopharmaceutical customers across horizontal segments (drug substance, drug product, specialty chemicals), supported by co-investment agreements with select anchor clients. The company goes to market through direct sales and account management, industry conference presence (CPhI, BIO-Europe, ChemOutsourcing, ISPE), and content marketing via its knowledge center, with no third-party distribution channels.

Carbogen Amcis firmographics

Firmographics
Name
Carbogen Amcis
Legal name
CARBOGEN AMCIS AG
Website
https://carbogen-amcis.com
Company type
Private
Founded year
1987
Operating status
Operating
Headcount range
501–1,000 employees
Ownership category
akta.pro rank

Carbogen Amcis industry classification

Industry
Product category
Pharmaceutical Contract Development and Manufacturing (CDMO)
NAICS
Pharmaceutical Preparation Manufacturing (325412), Biological Product (except Diagnostic) Manufacturing (325414), Pharmaceutical and Medicine Manufacturing (32541)
SIC
Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAGABAA
Small-Molecule API & Intermediates CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
SECONDARYHLAGABAB
Small-Molecule Drug Product (Solid/Oral/Parenteral) CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
SECONDARYHLAGABAG
Drug Substance–Drug Product Integrated CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
SECONDARYHLAGABAC
Biologics (mAbs/Recombinant Proteins) CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)

Keywords

  • Contract pharmaceutical manufacturing
  • API development services
  • Sterile drug product manufacturing
  • Highly potent API manufacturing
  • Antibody drug conjugate services

Where Carbogen Amcis is headquartered

Location

Headquarters

HQ city
Bubendorf
HQ country
Switzerland
HQ region
Europe

Offices9 records

Markets served

Carbogen Amcis business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Operations, Infrastructure, Supply Chain, Technology or R&D, Marketing or Sales

Revenue model

  1. Contract Development and Manufacturing Services: CDMO services for drug substance and drug product development and manufacturing, including clinical and commercial API production, sterile drug product manufacturing, and analytical services. Revenue generated through project-based contracts, typically with upfront payments (40%), milestone payments (50%), and final payments (10%) upon delivery of reports.
  2. Specialty Chemicals (Vitamin D and Cholesterol): Production and sale of Vitamin D analogs, Vitamin D2, cholesterol, and lanolin derivatives for pharmaceutical, cosmetic, food supplement, and industrial applications.

Pricing tiers

ModelBillingPrice
OtherMulti-year contractClinical Trial Phase Services - Custom project pricing
OtherMulti-year contractISPE Workshop Participation

Go-to-market motion1 record

Distribution channels1 record

Marketing channels5 records

Carbogen Amcis product offering

Product offering

Core offering

Carbogen Amcis is a pharmaceutical Contract Development and Manufacturing Organization (CDMO) providing integrated drug substance (API) and drug product development and manufacturing services. It serves pharmaceutical and biopharmaceutical companies with capabilities spanning non-GMP and GMP API manufacturing, sterile injectable drug product manufacturing, highly potent compound handling, ADC/bioconjugation, and specialty Vitamin D and cholesterol products, across 8 manufacturing sites in Europe and China.

Product overview

CARBOGEN AMCIS is a Contract Development and Manufacturing Organization (CDMO) offering integrated pharmaceutical services from drug substance to drug product. The portfolio consists of three core service pillars: Drug Substance CDMO (API development and manufacturing), Sterile Drug Product CDMO (injectable drug manufacturing), and Cholesterol & Vitamin D Specialities. Supporting these core areas are specialized capability modules including SPRINT early-phase services, Highly Potent API manufacturing, ADC & Bioconjugation, Chromatography, Flow Chemistry, and Crystallization. The company operates 8 manufacturing sites across Switzerland, UK, France, Netherlands, and China, providing services from gram-scale development through commercial production up to multi-tonne scale.

Differentiator

Problem solved

Functional benefit

Products and services

  • Drug Substance CDMO Services
  • Sterile Drug Product CDMO Services
  • SPRINT Early-Phase Development Services
  • Highly Potent API (HiPo) Manufacturing
  • ADC & Bioconjugation Services
  • Vitamin D Analogs and Vitamin D2
  • Cholesterol and Lanolin Derivatives

Quantifiable outcome

  • Successful completion of unannounced NMPA GMP inspection with no observations identified at Shanghai facility
  • +3 more outcomes

Companies that use Carbogen Amcis

Customer profile

Named customers5 records

Segments3 records

Ideal customer profiles3 records

Carbogen Amcis technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature7 records

Carbogen Amcis partnerships and signals

Strategic signal

Partnerships

One partnership is on record.

  • Celonic GroupcoreStrategic or Co-development Partner · 27 October 2025Strategic alliance between Celonic Group and CARBOGEN AMCIS AG to develop and manufacture antibody drug conjugates (ADCs). The partnership aims to create an integrated ADC development platform amid rising demand, leveraging their respective expertise and expanding infrastructure to improve speed and quality.

Scale indicators9 records

Recent moves11 records

Expansion highlights5 records

Carbogen Amcis competitors and assessment

Company assessment

Broad incumbents

  • Eurofins CDMO (formerly Alpharma/IIT Research Institute): Global contract services group with CDMO capabilities spanning API development, HPAPI, and drug product services. Comparable as a broader-incumbent CDMO with overlapping capabilities but operating as part of a much larger diversified testing/services platform.
  • Lonza: Swiss-headquartered global CDMO leader with massive small-molecule API, biologics, and cell-and-gene therapy manufacturing footprint. Comparable as a larger Swiss CDMO operating across overlapping modalities, but orders of magnitude larger and serving biotech as well as big pharma.

Direct peers

  • Sterling Pharma Solutions: UK-headquartered CDMO specializing in small-molecule API development and HPAPI manufacturing. Closely comparable on UK-based HPAPI operations and overlap with Carbogen's Manchester site.
  • Recipharm: European CDMO offering integrated drug substance and drug product services including sterile fill-finish. Comparable as a multi-site European CDMO targeting pharma customers with similar project-based service model.
  • WuXi STA (WuXi AppTec): China-based large-scale CDMO subsidiary of WuXi AppTec offering end-to-end small-molecule API and drug product services. Comparable as a CDMO peer of similar integrated scope with significant Asian manufacturing capacity overlapping Carbogen's Shanghai presence.
  • Piramal Pharma Solutions: Indian-headquartered CDMO with strong HPAPI and ADC capabilities across global sites. Comparable on HPAPI specialization, ADC services, and Indian ownership/operational heritage similar to Dishman Carbogen Amcis.
  • Aenova Group: German CDMO providing solid dosage forms, sterile fill-finish, and API services for pharma customers. Comparable as a mid-sized European integrated CDMO serving similar big-pharma customer base.
  • Hovione: Privately-held Portuguese CDMO specializing in API development, HPAPI handling, and particle engineering. Closely comparable on specialty HPAPI capabilities, integrated drug substance-drug product services, and family-owned private ownership profile.
  • Siegfried Holding: Swiss-headquartered integrated small-molecule CDMO with drug substance and drug product services across multiple global sites. Most directly comparable peer given shared Swiss heritage, integrated DS+DP model, and similar enterprise-scale customer mix.
  • Cambrex: US-based small-molecule API CDMO acquired by Permira. Directly comparable on small-molecule API development, HPAPI capabilities, and analytical services for pharma clients across clinical and commercial stages.

Market position

Strengths4 records

Weaknesses5 records

Competitive moat5 records

Key risks1 record

Key highlights6 records

Customer concentration

Carbogen Amcis social profiles

Digital presence

Carbogen Amcis compliance and trust

Trust signal

Compliance7 records

Carbogen Amcis financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Carbogen Amcis leadership team

Management profile

Number of profiles

Profiles9 records

Carbogen Amcis subsidiaries and ownership

Company hierarchy

Subsidiaries4 records

Carbogen Amcis funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Carbogen Amcis M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Carbogen Amcis

What does Carbogen Amcis do?

Carbogen Amcis is a pharmaceutical Contract Development and Manufacturing Organization (CDMO) providing integrated drug substance (API) and drug product development and manufacturing services. It serves pharmaceutical and biopharmaceutical companies with capabilities spanning non-GMP and GMP API manufacturing, sterile injectable drug product manufacturing, highly potent compound handling, ADC/bioconjugation, and specialty Vitamin D and cholesterol products, across 8 manufacturing sites in Europe and China.

Is Carbogen Amcis a public or private company?

Carbogen Amcis is a private company. It is classified as corporate owned and is currently operating.

When was Carbogen Amcis founded?

Carbogen Amcis was founded in 1987. It employs 501 to 1,000 people.

Where is Carbogen Amcis based?

Carbogen Amcis is headquartered in Bubendorf, Switzerland, in the Europe region.

How does Carbogen Amcis make money?

Two revenue lines are on record. Contract Development and Manufacturing Services are the primary driver. The others are specialty Chemicals (Vitamin D and Cholesterol).

Who are Carbogen Amcis's main competitors?

Broad incumbents on record are Eurofins CDMO (formerly Alpharma/IIT Research Institute) and Lonza. Direct peers are Sterling Pharma Solutions, Recipharm, WuXi STA (WuXi AppTec), Piramal Pharma Solutions, Aenova Group, Hovione, Siegfried Holding and Cambrex.

Does Carbogen Amcis have an API?

No public API is recorded for Carbogen Amcis.

What industry is Carbogen Amcis in?

Carbogen Amcis's product category is Pharmaceutical Contract Development and Manufacturing (CDMO). Its primary akta.pro industry code is HLAGABAA, Small-Molecule API & Intermediates CDMO, with a secondary code of HLAGABAB, Small-Molecule Drug Product (Solid/Oral/Parenteral) CDMO. Its NAICS code is 325412 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales